Torrent Pharmaceuticals Limited (500420) Earnings Call Transcripts

Torrent Pharmaceuticals Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Torrent Pharmaceuticals reported consolidated revenue of INR 4,197 crores, a significant increase of 42% year-over-year, driven by the acquisition of JB Pharma. Operating EBITDA rose 41% to INR 1,356 crores, with a combined operating EBITDA margin of 32.3%. Management maintained guidance for the full year, projecting organic growth in the India business to potentially exceed previous years, contingent on stable market conditions. The company also indicated that cost synergies from the JB Pharma acquisition are tracking ahead of expectations, with a target of INR 450 crores in synergies over three years.

Reported metrics

Guidance from management

Management maintained guidance for FY '27, projecting mid-teens organic growth for the India business, contingent on stable market conditions and no demand shocks.

What management said

So we have shared the full details on the JB call, but happy to share further here. There's no material update from the last call. Synergy execution remains on track. We had guided for up to INR 450 crores synergy by year 3 and about 20% of that in year 1. It's difficult to quantify quarter-by-quarter because we implement something as an action, but the actual reflection of the saving may take some time and may vary....

So the confidence on the revenue synergy getting delivered is certainly getting higher. But again, the time line remains the same. We have said that this year, we will not see any material synergies because all the changes take time to implement. But certainly, as we spend more and more time and see the business within our own hands, it's giving more comfort for sure.

What analysts pressed on

Analysts expressed concerns regarding the potential impact of geopolitical factors on domestic demand and the sustainability of growth in the U.S. and Germany markets, particularly due to supplier disruptions and competition in the semaglutide market.

Main topics on the call

• Revenue Growth Acceleration — Torrent's consolidated revenue for Q4 FY '26 was INR 4,197 crores, up 42% YoY, significantly boosted by the JB Pharma acquisition. Excluding JB Pharma, the base business still grew by 16%. Management stated, "Our 2 large...
• Strong Performance in India and Brazil — The India business grew 43% to INR 2,215 crores, outperforming the overall market growth. Brazil's revenue grew at a constant currency rate of 11%, with Torrent achieving a 17% growth rate, indicating strong market posit...
• Semaglutide Launch Success — The launch of semaglutide has been well-received, with Torrent capturing a 38% market share among generic players. Management noted, "The early advantage should help sustain high market share over the coming quarters," d...
• Cost Synergies from JB Pharma Acquisition — Management confirmed that cost synergies from the JB Pharma acquisition are on track, with an expected INR 450 crores in synergies over three years. They indicated that "the margin trajectory... is tracking above that so...

Read the full Torrent Pharmaceuticals Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 27 Torrent Pharmaceuticals Limited earnings call transcripts on record, spanning January 27, 2020 to July 30, 2026. Based on this history, Torrent Pharmaceuticals Limited reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

500420

Exchange

BSE

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

27

First call

January 27, 2020

Most recent

July 30, 2026

Reporting cadence

quarterly